Product/Composition:- | Cefixime Suspension |
---|---|
Strength:- | 100 mg/5 mL, 200 mg/5 mL |
Form:- | Suspension |
Reference Brands:- | Suprax(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Cefixime suspension inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, causing bacterial lysis. It effectively treats urinary and respiratory infections, especially in children. Benefits include convenient oral administration, rapid bacterial eradication, broad-spectrum activity, and suitability for pediatric use, providing reliable outpatient infection management.
Cefixime suspension is approved in the EU and US for treating urinary and respiratory tract infections, especially in pediatric patients. In the EU, brands like Cefixime are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality standards. In the US, FDA approval relies on extensive clinical data; generic formulations are widely available. Both regions require detailed dossiers, including clinical trial data, manufacturing practices, and pharmacovigilance plans, for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate seamless market access for cefixime suspension, ensuring adherence to European and US standards for safe, effective antibiotic therapy.